I don't envision a P2 for Kevetrin. I believe the data they are acquiring now will show the most effective dosage for Kevetrin and it will jump right to a P2/P3 or possibly even just a P3 thru Breakthrough Therapy or some other fast lane method of getting to patients sooner.
Once P1 is done, the world of oncology will have a pretty good idea that Kevetrin is a new class of treatment and recognize it's vast value. I also believe the real heavy hitters in biotech investment, such as Baker Brothers, will also have identified it's value by end of P1 and have taken some pretty strong positions. That is why I am putting my bet on the stock price taking off in the fall of this year. It will be the perfect storm of K,P, and B all coming together and the biotech world understanding the powerpacked lineup of products CTIX will be unleashing in a very, very short time (at least short for biotech).
Market Data 
Markets 
AI
